… antihypertensive therapies available in the Greek market for patients with … economic
evaluation aimed to assess the cost-effectiveness of dabigatran etexilate for six months of treatment …

… analysis suggests that dabigatran is generally cost-effective as an alternative to warfarin.
Treatment … Dabigatran etexilate is a newer direct thrombin inhibitor that does not cause liver …

… antihypertensive therapies available in the Greek market for patients with … economic
evaluation aimed to assess the cost-effectiveness of dabigatran etexilate for six months of treatment …

… for economic evaluations [… Economic Evaluation Reporting Standards statement provides
a list of 24 items and accompanying recommendations for reporting economic evaluations (…

… not differ significantly between dabigatran etexilate and enoxaparin. Dabigatran etexilate was
less … in administration costs. The cost of prophylaxis for THR patients, including drugs and …

… -world evaluations of therapy effectiveness should also assess therapy compliance, which
was not reported in the clinical trials, to provide essential data for future economic evaluations …

… This study aims to review the existing economic evaluations of novel oral anticoagulants (…
This study highlights the economic evaluation methodology of NOACs in patients with AF …

… atrial fibrillation OR atrial fibrillation AND nonvitamin-K-antagonists OR new oral anticoagulants
OR novel oral anticoagulants OR dabigatran OR … in this meta-analysis that was not pre-…

… antihypertensive therapies available in the Greek market for patients with … economic
evaluation aimed to assess the cost-effectiveness of dabigatran etexilate for six months of treatment …

… OBJECTIVES: Atrial fibrillation (AF) is the most common cardiac rhythm disorder; it … The
aim of this study was to estimate cost-effectiveness of dabigatran 110 mg and 150 mg BID as a …